Cannabis does have painkilling properties, though it works differently from traditional painkillers and its effectiveness varies by pain type. About 39% of chronic pain patients using medical cannabis experience meaningful improvements in pain, function, or overall well-being within three months. That’s a real effect, but it’s far from universal, and the strength of relief is generally moderate rather than dramatic.
How Cannabis Reduces Pain
Your body already produces its own cannabis-like molecules called endocannabinoids. These molecules bind to two types of receptors (CB1 and CB2) spread throughout your brain, spinal cord, and peripheral nerves. When you use cannabis, THC mimics these natural molecules and plugs into the same receptors, dialing down pain signals before they fully register.
THC reduces pain through at least three distinct molecular pathways. It activates CB1 receptors in the brain and spinal cord, which dampens the relay of pain signals from your nerves to your brain. It also activates CB2 receptors, which are concentrated in immune cells and help reduce inflammation-driven pain. And it interacts with glycine receptors in the spinal cord, a separate mechanism that produces its own analgesic effect independent of the cannabinoid receptors. This multi-target approach is part of why cannabis can affect several types of pain, though none of them as powerfully as a drug designed to hit one pathway hard.
THC and CBD Play Different Roles
THC is the primary painkilling compound in cannabis. It’s the component with the longest history of analgesic use and the strongest clinical evidence. It directly activates the cannabinoid receptors that suppress pain signaling, and it alters how your brain processes the emotional unpleasantness of pain, which is why some users report that pain is still present but “bothers them less.”
CBD contributes differently. It appears to have analgesic properties at high doses, with the strongest evidence in nerve pain models. But CBD’s main role in pain management is as an anti-inflammatory. In rheumatoid arthritis research, CBD was shown to reduce production of inflammatory molecules (IL-6, IL-8, and an enzyme that breaks down joint tissue) by targeting the inflamed cells themselves. Notably, CBD preferentially affects cells that are already in an inflammatory state, leaving healthy cells relatively undisturbed. This selectivity makes it a promising option for inflammatory conditions, though the human evidence is still catching up to the lab findings.
For pain relief specifically, products containing THC or a combination of THC and CBD consistently outperform CBD-only products in clinical trials.
Where the Evidence Is Strongest
Cannabis performs best against nerve pain (neuropathic pain), which is notoriously difficult to treat with conventional medications. Standard treatments for nerve pain, including certain antidepressants and anticonvulsants, only achieve a 50% pain reduction in roughly one out of every 3.5 to 7.7 patients treated. Even strong opioids only hit that mark in about one in 4.3 patients.
Cannabis doesn’t blow those numbers away, but it holds its own. A meta-analysis found that THC reduced nerve pain intensity by about 9 points on a 100-point scale compared to placebo, and patients using THC were 1.85 times more likely to achieve at least a 30% reduction in pain. Combined THC/CBD preparations showed similar results, with patients 1.76 times more likely to hit that 30% threshold. The evidence quality is moderate to low, but it’s consistent enough that clinical guidelines now position cannabis-based treatments as a third- or fourth-line option for chronic nerve pain when standard therapies haven’t worked.
For chronic pain more broadly, a comparative effectiveness study found that medical cannabis users had 2.6 times the odds of responding to treatment compared to patients on standard prescription medications. Response rates held steady between three and six months, suggesting the benefits don’t fade quickly for those who do respond.
Cannabis and Opioid Use
One of the more practical findings involves cannabis as a complement to, rather than replacement for, other pain medications. In states with medical marijuana laws and active dispensaries, strong short-acting opioid prescriptions dropped by about 13% relative to states without such laws. Among colorectal cancer patients specifically, total opioid consumption fell significantly when medical cannabis was accessible.
This doesn’t mean cannabis replaces opioids for severe pain. It means that for some patients, adding cannabis to their pain management allows them to use lower doses of stronger drugs, which reduces the risks that come with high-dose opioid use.
How Medical Cannabis Dosing Works
If you’re using cannabis for pain through a medical program, the standard approach is to start low and increase gradually. Expert consensus recommends beginning with 5 mg of CBD twice daily, increasing by 10 mg per day every two to three days, up to 40 mg of CBD daily. If that doesn’t provide enough relief, THC is added at 2.5 mg per day, then increased by 2.5 mg every two to seven days.
People who are older, on multiple medications, or have mental health conditions are typically started even more conservatively: 5 mg of CBD once daily, with THC added later at just 1 mg, increased by 1 mg per week. The ceiling for both protocols is 40 mg of THC daily, though most patients find their effective dose well below that. This slow approach minimizes side effects and helps identify the lowest dose that provides meaningful relief.
Side Effects and Risks
About one in four medical cannabis users for chronic pain reports some type of adverse effect. The most common category is psychiatric: roughly 14% of users experience issues like anxiety, mood changes, or paranoia. Memory impairment occurs in about 5% of long-term users. These rates increase with longer use, likely because tolerance builds over time and people increase their doses to maintain the same effect.
Serious adverse events, including those severe enough to make people stop using cannabis, occur in fewer than 1 in 20 patients. Dependence develops in a similar range, around 4% of medical users, though withdrawal symptoms (sleep disruption, irritability, appetite changes) are reported much more frequently when people do stop. Most safety data only extends to about a year of use, so the long-term picture beyond that remains unclear.
The overall evidence quality for safety data is rated very low, not because the harms are necessarily severe, but because the studies tracking them tend to be observational rather than controlled. This means the true rates could be somewhat higher or lower than current estimates suggest.
How It Compares to Traditional Painkillers
Cannabis is not as potent as opioids for acute or severe pain. It’s not a replacement for ibuprofen after surgery or morphine for a broken bone. Its strength lies in chronic, ongoing pain conditions where conventional options have either stopped working, cause intolerable side effects, or carry serious risks with long-term use.
For nerve pain specifically, cannabis performs in a comparable range to first-line prescription options, which is notable given that those options often fail. For inflammatory pain, the evidence is more mixed in humans, though the biological rationale, particularly for CBD, is strong. For general chronic pain, about 4 in 10 users get meaningful relief, which is a modest but real success rate for a condition where many treatments fail entirely.
The International Association for the Study of Pain has called for more rigorous research before making definitive clinical recommendations, reflecting the reality that while the signal for pain relief is consistent, the quality of evidence still lags behind what exists for established analgesics.